Jay Mazelsky

Jay Mazelsky became president and CEO of IDEXX Laboratories in 2019, taking the helm of the world's leading veterinary diagnostics company. IDEXX operates a tightly integrated platform: it places diagnostic analyzers in veterinary clinics (the "razor"), then generates recurring revenue from consumable test kits, reference laboratory services, and practice management software (the "blades"). This model has produced revenue retention rates above 95% and organic growth consistently in the high single digits. Under Mazelsky's leadership, IDEXX has expanded its test menu with innovations like SDMA (a kidney disease biomarker that detects illness months earlier than traditional tests) and advanced reference lab panels. He has pushed international expansion aggressively, with international markets now representing over 40% of revenue. The pet humanization mega-trend — where owners increasingly treat pets as family members and spend accordingly on healthcare — provides a powerful secular tailwind. Mazelsky's decisions on R&D investment in new diagnostic assays, pricing strategy for consumables, and geographic expansion pace are the critical drivers of IDEXX's market valuation. The company trades at a premium multiple reflecting its dominant competitive position and the durability of pet healthcare spending even through economic downturns.